Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - BIOSPECIFICS TECHNOLOGIES CORP | ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 23, 2020
BIOSPECIFICS TECHNOLOGIES CORP.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-34236
|
11-3054851
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
35 Wilbur Street
Lynbrook, NY
|
11563
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 516.593.7000
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, Par Value $0.001
|
BSTC
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Introductory Comment
Throughout this Current Report on Form 8-K, the terms "we," "us," "our" and "Company" refer to BioSpecifics Technologies Corp.
|
Item 7.01
|
Regulation FD Disclosure
|
On March 23, 2020, the Company updated the Corporate Presentation slides on its website. The presentation can be accessed at www.biospecifics.com.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
|
Exhibit No.
|
Description
|
|
Corporate Presentation Slides
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOSPECIFICS TECHNOLOGIES CORP.
|
||
|
By:
|
/s/ Patrick Hutchison
|
|
|
Patrick Hutchison,
|
||
|
Chief Financial Officer
|
||
Date: March 23, 2020